Article content
Alberta-based pharmaceutical companies with COVID-19 vaccines in the works are urging the provincial government to move quickly to support the development of a domestic vaccine industry.
The Alberta government which put out a call for proposals in March for projects that would bolster long-term vaccine capacity in the province has since received 17 submissions from companies both inside and outside Alberta, proposing to do everything from early-stage research and development, to manufacturing and final production. All of the interested companies were asked how they would support the health of Albertans during COVID-19 and any future variants, as well as how they would support the long-term growth of the pharmaceutical sector in Alberta and local job creation.
Sustainable Marine adopts new technology energyglobal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from energyglobal.com Daily Mail and Mail on Sunday newspapers.
UK-based Sustainable Marine is adopting cutting-edge aerospace and wind energy technology in a new project to drive the evolution of tidal turbine foils.
The marine renewables specialist is leading the EvoFoil project in partnership with German organisations M&D Composites Technology and Leibniz Universität Hannover Institute of Production Engineering and Machine Tools.
The EvoFoil project aims to deliver a series of design innovations to optimise the performance of tidal turbine foils while driving down production and operation costs.
Sustainable Marine is receiving advisory services and up to $578,000 (€480,000) in research and development funding from
the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) for the two-year project.
Nano One Materials Corp : Nano One Advances Joint Development Work with Asian Cathode Producer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Bold Therapeutics Inc.
While viral mutations are inevitable, the potential for mutations to reduce the effectiveness of vaccines or potentially even render them ineffective is a source of considerable concern, particularly in countries with a vaccination-centric strategy. For example, the E484K mutation, first detected in both the South African (B.1.351) and Brazilian (B.1.1.28) variants – and more recently in the UK variant (B.1.1.7) – is a spike protein mutation that has been shown to be immune-evading, allowing previously infected patients to become reinfected and potentially allowing vaccinated patients to become infected. In just the past few weeks, a new Eek variant of concern (with both E484K and N501Y mutations) has emerged in Japan